INDIVIDUALIZATION OF TREATMENT OF HYPERLIPOPROTEINEMIC DISORDERS

被引：2

作者：

AZARNOFF, DL ^{[1
]}

机构：

[1] UNIV KANSAS, MED CTR, CLIN PHARMACOL TOXICOL CTR, KANSAS CITY, KS 66103 USA

来源：

关键词：

D O I：

10.1016/S0025-7125(16)32109-5

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1129 / 1135

页数：7

共 24 条

[1]

[Anonymous], 1972, JAMA-J AM MED ASSOC, DOI [DOI 10.1001/JAMA.1972.03200070084015, 10.1001/jama.1972.03200070084015]

[2]

BEUMONT JL, 1970, B WORLD HEALTH ORGAN, V43, P891

BRESSLER, R ;

NOWLIN, J ;

BOGDONOFF, MD .

[4]

BRIDGMAN JF, 1972, LANCET, V2, P506

[5]

CARLSON LA, 1972, LANCET, V1, P865

[6] A SYSTEM FOR PHENOTYPING HYPERLIPOPROTEINEMIA [J].

FREDRICK.DS ;

LEES, RS .

FREDRICK.DS ;

LEVY, RI ;

LEES, RS .

[8]

FREDRICKSON DC, 1966, METABOLIC BASIS INHE

[9]

FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499

[10]

GALLO DG, 1965, P SOC EXP BIOL MED, V120, P60